The global pork industry operates on an enormous scale. With pork representing roughly one-third of all meat consumed globally, the sector underpins food security and rural economies on every continent. It is a sophisticated value chain built over decades of expertise, investment, and collaboration.
And it is under increasing pressure.
What has changed is the pace and complexity of swine disease challenges. Historically, the industry has seen a significant new disease emerge approximately every 10 to 15 years, but the global rate of pathogen emergence has been accelerating. Higher animal densities, international trade, climate change, and the continuous mutation of pathogens like PRRS that can outpace existing control strategies are all compounding the pressure.
The disease management toolkit needs a stronger foundation.
The industry’s response to disease is already sophisticated. Biosecurity, vaccination, nutrition, optimized housing environments, and data-driven surveillance - each of these pillars contributes to herd health. Individually, they reduce risk. Together, they form a system.
But each of these interventions operates through the same ultimate interface: the biology of the pig itself. Every vaccine depends on the animal mounting an effective immune response. Every biosecurity investment reduces the pathogen challenge the animal’s own defenses must manage. Every nutrition strategy works, in part, by supporting the animal’s underlying physiology.
This creates a powerful opportunity. If the intrinsic biological capacity of pigs to withstand and recover from health challenges can be improved through genetics, the effectiveness of every other investment is simultaneously enhanced. Genetic disease resilience is the substrate that makes the entire system more effective.
Resilience, not resistance: why the distinction matters
Two genetic strategies are often discussed in the context of disease management, and the difference between them is strategically significant.
Disease resistance refers to the ability to limit or prevent pathogen establishment, replication, or spread. A resistant animal can limit pathogen load - ideally preventing infection altogether. Resistance is a powerful outcome when it can be achieved. However, resistance is pathogen-specific. A resistance mechanism engineered or selected for a specific pathogen may offer reduced protection as that pathogen mutates. Moreover, resistance to one disease offers no benefit against another.
Disease resilience is fundamentally different. Enhanced disease resilience refers to the capacity to withstand and recover from infection, regardless of the specific pathogen involved. A resilient animal may carry a measurable pathogen burden, but the clinical and productive consequences are substantially reduced. Resilience operates through broader biological mechanisms. A herd with strong genetic resilience is better equipped to cope not only with today’s diseases, but with novel and emerging pathogens for which no vaccine or targeted treatment yet exists.
Two Main Genetic Approaches to Disease Management
Gene editing offers a direct route to resistance through targeted genome modifications. However, protection is specific to the pathogen it was designed to address and can erode as that pathogen mutates. Regulatory approval for gene-edited livestock remains inconsistent across markets, and consumer acceptance is unsettled, adding commercial risk on top of the biological constraints.
Genomic selection takes a different route. It uses high-density genetic marker data to identify animals that are naturally more resilient (or resistant) to disease. Genomic selection for disease resilience is complex to execute, requiring large datasets from animals in commercial challenge conditions and sophisticated statistical models. But the gains are permanent and cumulative, building across generations, heritable across commercial herds worldwide, and broad-spectrum in their value - compounding as the disease landscape continues to evolve.
A new era in disease management
The convergence of these insights - the increasing disease pressure, the systemic nature of effective disease management, and the progress of genomic tools - points toward a clear direction for the industry: proactive, layered, and collaborative disease management, with genetic disease resilience as its biological foundation.
This is the ambition behind R3silience, Topigs Norsvin’s dedicated product for enhanced disease resilience. Built on large-scale phenotyping from animals under commercial disease challenge conditions, sophisticated genomic models, and sustained investment in health-related traits, R3silience is designed to deliver what the industry increasingly needs: pigs that are inherently better equipped to withstand pathogen pressure, respond to health challenges, and maintain productive performance - across geographies, production systems, and whatever disease landscape lies ahead.
Topigs Norsvin is a global leader in pig genetics, combining science-driven breeding with practical solutions for sustainable pork production worldwide.
